| Name | Splitomicin |
| Description | Splitomicin (1-Naphthalenepropanoic Acid) (IC50 of 60 μM), a specific inhibitor of NAD(+)-dependent histone deacetylase Sir2p, displays a high activity in a cell-based assay. |
| In vitro | Splitomicin inhibits Sir2p deacetylase activity by altering or blocking access to the acetylated histone binding pocket. [1] Splitomicin inhibits platelet aggregation induced by thrombin, collagen, AA and U46619 via inhibition of cyclic AMP phosphodiesterase activity and subsequent inhibition of intracellular Ca(++) mobilization, TXB2 formation and ATP release. [2] |
| In vivo | In a photochemical injury mouse model, splitomicin (80 mg/kg/d i.p.) enhances tissue factor activity in the arterial vessel wall and promotes carotid artery thrombus formation. [3] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 19.8 mg/mL (99.89 mM), Sonication is recommended.
Ethanol : 19.8 mg/mL (99.89 mM), Sonication is recommended.
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (10.09 mM), Sonication is recommended.
|
| Keywords | Splitomycin | Splitomicin | SIRT2p | Inhibitor | inhibit | Histone deacetylases | HDAC |
| Inhibitors Related | Valproic acid sodium salt | Panobinostat | Theophylline monohydrate | Methoxyacetic acid | Sodium 4-phenylbutyrate | Manganese chloride (tetrahydrate) | Curcumin | Valproic Acid | Sodium butanoate | Theophylline | 4-Phenylbutyric acid | Nicotinamide |
| Related Compound Libraries | DNA Damage & Repair Compound Library | Bioactive Compound Library | HIF-1 Signaling Pathway Compound Library | Post-Translational Modification Compound Library | Inhibitor Library | NO PAINS Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Human Metabolite Library |
United States
